orbit™ Osteogenesis Imperfecta (OI) Clinical Research

Clinical Study for Patients With Osteogenesis Imperfecta

We are investigating a study medicine for the treatment of OI.

Why are we doing this study?

The purpose of this study is to evaluate how a new investigational medicine called setrusumab can safely and effectively reduce fractures in pediatric and young adult patients with OI. Setrusumab is called an investigational medicine because it is not approved by Health Authorities and is still being tested in research studies.

Certain treatments for OI slow bone resorption. Less bone resorption can increase the density of bones, but the bone remains abnormal and some OI patients still have fractures. Setrusumab is expected to work in a different way by building new bone, as well as slowing bone resorption. In this study, we will see if patients who receive setrusumab have fewer fractures over the study period.

Consider participating if you:

- Are between the ages of 5 and 26
- Have OI Types I, III, or IV
- Had at least one fracture in the past year, two fractures in the past 2 years, or a tibia, humerus, or femur fracture in the past 2 years
  - Fractures can be self-treated or assessed by your doctor
- Agree to not take other therapies that may impact the bones during this study, including bisphosphonates

Why do I need to stop my bisphosphonates?

In order to evaluate the effects of setrusumab, we need to assess patients who are not on other medications that also impact the bone during the time of the study. This will allow us to best assess the efficacy and safety of setrusumab.

What is involved?

Study duration:

Screening Period:
Up to 1 month

Study Treatment Period:
1-2 years, with a maximum study enrollment time of 24 months

Treatment Extension Period:
Receive setrusumab for at least 12 months or until commercially available

Study treatment:

- For Phase 3, you will be assigned to receive either the study medicine or placebo (a medicine with no active substance). Two people will receive study medicine for every one person who receives placebo. After the study treatment period, everyone (100%) will receive the study medicine.

Phase 3
- setrusumab
- placebo

Study visits:

- You will receive study medicine and have lab tests and assessments at monthly study visits. The number of visits you will have will depend on when you enroll in the study.

Support is provided for travel costs to clinic visits.

What to expect:

- Monthly infusion of study medicine
- Blood and urine tests
- Monthly physical examinations
- Regular X-rays and bone density tests
- Heart tests
- A smartphone app to track your health and fractures (a smartphone will be provided if you don't have one)

To learn more about this study, please contact OIstudyinfo@ultragenyx.com.

ultragenyx

MRCM-UX143-00010 09Nov2023

cosmic™ Osteogenesis Imperfecta (OI) Clinical Research

Clinical Trial for Children With Osteogenesis Imperfecta (OI)

We are investigating a medicine for the treatment of OI.

Why are we doing this study?

The purpose of this study is to learn more about how a new medicine called setrusumab can reduce fractures compared to bisphosphonates in children with OI, as well as to study the safety of setrusumab. Setrusumab is called an investigational drug because it is still being researched and can only be obtained through a clinical study. The goal of the study is to learn more about the best use of setrusmamb so that the data can be submitted to Health Authorities, like the FDA.

Your bones are a living tissue and the cells are constantly turning over— making new bone (bone formation) and breaking preexisting bone (bone resorption). Certain treatments for OI slow bone resorption. Less bone resorption can increase the density of bones, but the bone remains abnormal and some patients still have fractures. Setrusumab is expected to work in a different way. Setrusumab works by building new bone, as well as slowing bone resorption. In this study, we will see if children who receive setrusumab have fewer fractures over 2 years.

Consider having your child participate if he or she:

- Is at least 2 but less than 7 years of age
- Has a clinical diagnosis of OI Types I, III, or IV
- Has had at least one fracture in the past year **or** two fractures in the past 2 years **or** one femur, tibia, or humerus fracture in the past 2 years
- Has received intravenous bisphosphonate therapy for treatment of OI

What is involved?

Study duration:

Screening Period:
Up to 1 month
Screening includes assessments to confirm you meet the entry requirements for the study, and will include lab tests, imaging and physical examination

Study Treatment Period:
2 years

Treatment Extension Period:
Receive setrusumab a minimum of 12-months or until commercial medicine is available

Study treatment:

Your child will be assigned by chance, like flipping a coin, to receive study treatment with either:

- setrusumab infusions (50% chance)
  or
- bisphosphonate infusions (50% chance)

You will know which of these your child receives. If your child receives setrusumab, infusions will be once a month. If your child receives bisphosphonates, your child's doctor will choose the treatment plan based on local guidelines; the timing of infusions will depend on the plan chosen.

Study visits:

Your child will participate in the study for up to 24 months, with an option to extend in the open label extension. Your child's visits will include lab tests and assessments. If your child receives setrusumab, infusions will be given at each visit. If your child receives bisphosphonates, the study doctor will tell you which visits will include infusions.

What to expect:

- Infusions of setrusumab or bisphosphonates into your child's arm
- Blood and urine tests
- Monthly physical examinations
- X-rays (every 12 months) and bone density tests (every 6 months)
- Heart tests (every 6 months)
- A smartphone app to track your child's health and fractures (a smartphone will be provided if you don't have one)

Where allowed, support is provided for travel costs to clinic visits.

To learn more about this study, please contact OIStudyinfo@ultragenyx.com

At Ultragenyx, we are committed to bringing patients new treatments for rare and ultrarare diseases.

MRCM-UX143-00051 07Sep2023